SYK and acute myeloid leukemia: In order to explore the role of activated SYK as a biomarker in patients with AML, determine whether SYK activity correlates with patient outcome, and evaluate the efficacy of targeting this kinase in vivo in AML blasts, a method is required for accurately measuring the levels of SYK activity in patient samples.